Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Planta Med ; 88(13): 1223-1232, 2022 Oct.
Article de Anglais | MEDLINE | ID: mdl-34715694

RÉSUMÉ

Cannabis sativa is a millenary medicinal plant. However, contrary to worldwide paradigm-shifting, countries like Brazil still prohibit C. sativa cultivation and its medicinal use, even though many populations use aerial parts and roots of this plant for healthcare. As such, the objective of this work was to identify substances in the samples of the C. sativa roots, tracing a correlation with antitussive and expectorant effects. Therefore, samples of C. sativa roots were donated by the Polícia Federal Brasileira, and its aqueous extract (AECsR) was prepared with subsequent lyophilization, to maintain the material stability. After that, the material was analyzed by LC-MS to observe its chemical profile. Four samples (AECsR-A, B, C, and D) were tested in animal models of citric acid-induced cough (0.4 M) and phenol red expectoration (500 mg/kg). Using LC-MS it was possible to identify 5 molecules in C. sativa roots: p-coumaroyltyramine, tetrahydrocannabinol-C4, feruoiltyramine, anhydrocanabisativine, and cannabisativine. In experimental protocols, male mice (Mus musculus) were treated with samples of AECsR at doses of 12.5, 25, or 50 mg/kg regardless of the pharmacological test. In these tests, all samples showed the potential to treat cough and promote fluid expectoration, differing only in the dose at which these effects were observed. Therefore, the data showed that the C. sativa roots of the Brazilian Northeast showed antitussive and expectorant effects, even with intense secondary metabolites' variation, which alters its potency, but not its effect. This highlights the importance of this medicinal plant for future therapy and corroborates to traditional use.


Sujet(s)
Antitussifs , Cannabis , Plantes médicinales , Souris , Animaux , Antitussifs/pharmacologie , Antitussifs/usage thérapeutique , Expectorants/pharmacologie , Expectorants/usage thérapeutique , Toux/induit chimiquement , Toux/traitement médicamenteux , Brésil , Phénolsulfonephtaléine , Chromatographie en phase liquide , Dronabinol/usage thérapeutique , Spectrométrie de masse en tandem , Plantes médicinales/composition chimique , Acide citrique/toxicité , Acide citrique/usage thérapeutique
2.
J Ethnopharmacol ; 278: 114259, 2021 Oct 05.
Article de Anglais | MEDLINE | ID: mdl-34058314

RÉSUMÉ

ETHNOPHARMACOLOGICAL RELEVANCE: Many studies are performed with the aerial parts of Cannabis sativa L. (Cannabaceae). However, roots remain poorly studied, despite citations in the scientific literature. The C. sativa roots are indicated for the treatment of pain, inflammation, fever, among other health problems. AIM OF THE STUDY: This study aimed to evaluate the antinociceptive, antipyretic, antiasthmatic, and spasmolytic activities of C. sativa roots in experimental models using mice and rats. MATERIAL AND METHODS: The chemical composition of the aqueous extract of C. sativa roots (AECsR) was evaluated by LC-MS. The antinociceptive activity was assessed in mice by the induction of writhing with acetic acid, paw licking with formalin, and reactivity in the hot plate test. Fever was induced by the administration of a suspension of Saccharomyces cerevisiae in young rats. The asthmatic activity was performed with ovalbumin (OVA)-immunized mice with cellular and histological analysis. Finally, the spasmolytic activity was performed using mice isolated trachea. For in vivo studies, the doses were 12.5, 25, or 50 mg/kg whereas for in vitro, the concentration of AECsR was 729 µg/mL. RESULTS: From the LC-MS data, we identified p-coumaroyltyramine, feruloyltyramine canabissativine in AECsR. The extract promoted a reduction of writhing in all tested doses (12.5, 25, or 50 mg/kg). Similarly, it reduced the pain in the formalin test at doses of 12.5 and 50 mg/kg (first phase) and 12.5 and 25 mg/kg (second phase). In the hot plate test, the doses of 12.5, 25, and 50 mg/kg promoted antinociceptive effect at different times, and the lowest dose maintained its action in the analyzes performed at 60, 90, and 120 min after administration. The anti-inflammatory activity of AECsR was observed in the mouse model of asthma, reducing the total leukocyte count in the bronchoalveolar fluid (BALF) at a dose of 25 mg/kg, as well as reducing eosinophilia in all tested doses (12.5, 25, and 50 mg/kg). Histological analysis of lungs stained with H&E and PAS showed a reduction in the number of inflammatory cells in the perivascular and peribronchial region, as well as reduced mucus production. CONCLUSION: The results suggest that AECsR promotes pain control, either by a central or inflammatory mechanism, and has antiasthmatic activity. However, there was no antipyretic or spasmolytic effect.


Sujet(s)
Analgésiques/pharmacologie , Antiasthmatiques/pharmacologie , Cannabis/composition chimique , Extraits de plantes/pharmacologie , Analgésiques/administration et posologie , Analgésiques/isolement et purification , Animaux , Antiasthmatiques/administration et posologie , Antiasthmatiques/isolement et purification , Antipyrétiques/administration et posologie , Antipyrétiques/isolement et purification , Antipyrétiques/pharmacologie , Brésil , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Fièvre/traitement médicamenteux , Inflammation/traitement médicamenteux , Mâle , Souris , Douleur/traitement médicamenteux , Parasympatholytiques/administration et posologie , Parasympatholytiques/isolement et purification , Parasympatholytiques/pharmacologie , Extraits de plantes/administration et posologie , Racines de plante , Rats , Rat Wistar
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE